Fabry disease prevalence in patients with familial Mediterranean fever: A cohort study



Alpha-galactosidase, Fabry disease, Familial Mediterranean fever


Background/Aim: Fabry disease is an X-chromosome inherited disease, which constitutes a rare disease group. Fabry disease has a wide spectrum of symptoms and some of these symptoms that are seen in other diseases. Familial Mediterranean fever (FMF) is a common disease in countries along the Mediterranean coast, including our country. Although typical episodes of recurrent high fever and abdominal pain occur, patients can also present with nonspecific symptoms and signs. This study aimed to investigate the presence of Fabry disease in patients with FMF. Methods: Information about this cohort study was given to all patients who were followed up with a diagnosis of FMF. Those who agreed to sign the informed consent form were included in the study. Fabry disease screening was performed by galactosidase alfa (GLA) gene analysis in female patients and by examining lysosomal alpha galactosidase A (AGALA) enzyme activity in male patients. When enzyme activity was found to be low in male patients, a GLA gene analysis was also performed. Results: Fabry disease was screened in a total of 189 patients with familial Mediterranean fever, and it was not detected in any of our patients. Low AGALA enzyme activity was detected in approximately 20% of the male patients. In the GLA gene analysis performed on these patients, any genetic mutation that could be associated with Fabry disease was not detected. Conclusion: People with Fabry disease or FMF can present with common symptoms, such as arthritis, proteinuria, and abdominal pain. In our study, Fabry disease was not found in any of patients who had a diagnosis of FMF. However, only a few publications on this subject are available. In studies conducted in our country and around the world, it has been shown that GLA gene mutations that may cause Fabry disease can be detected in patients with FMF. However, such a mutation was not detected in our study.


Download data is not yet available.


Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;22(5):30. doi: 10.1186/1750-1172-5-30.

Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc Natl Acad Sci U S A. 1988;85(11):3903-7. doi: 10.1073/pnas.85.11.3903.

Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122-38. doi: 10.1097/00005792-200203000-00003.

Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-54. doi: 10.1001/jama.281.3.249.

Houge G, Skarbøvik AJ. Fabrys sykdom--en diagnostisk og terapeutisk utfordring [Fabry disease--a diagnostic and therapeutic challenge]. Tidsskr Nor Laegeforen. 2005;125(8):1004-6.

Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236-42. doi: 10.1111/j.1365-2362.2004.01309.x.

Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227-53. doi: 10.1016/0002-9343(67)90167-2.

Ben-Chetrit E, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009;61(10):1447-53. doi: 10.1002/art.24458.

Heller H, Gafni J, Michaeli D, Shahin N, Sohar E, Ehrlich G, et al. The arthritis of familial Mediterranean fever (FMF). Arthritis Rheum. 1966 Feb;9(1):1-17. doi: 10.1002/art.1780090102.

Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med. 2001;345(24):1748-57. doi: 10.1056/NEJMra010200.

Yavuzbilge G, Okuyucu M, Civil Y, Günaydın S, Avcı B. Assessment of serum TWEAK levels in patients with familial Mediterranean fever. J Surg Med. 2021;5(2):140-3. doi: 10.28982/josam.833593

Ozdogan H, Ugurlu S. Familial Mediterranean Fever. Switzerland: Springer International Publishing: Chapter 9. The Emerging Treatment in Familial Mediterranean: 2015:137-58.

Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10):1879-85. doi: 10.1002/art.1780401023.

Tumgor G, El C, Bucak IH, Yilmaz M. Association of Familial Mediterranean Fever and Crohns disease. Dicle Med J. 2013;40:301-3. doi: 10.5798/diclemedj.0921.2013.02.0275

Alghamdi M. Familial Mediterranean fever, review of the literature. Clin Rheumatol. 2017;36(8):1707-13. doi: 10.1007/s10067-017-3715-5. Epub 2017 Jun 18.

Monserrat L, Gimeno-Blanes JR, Marín F, Hermida-Prieto M, García-Honrubia A, Pérez I, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50(25):2399-403. doi: 10.1016/j.jacc.2007.06.062.

Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, et al. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013;44(2):340-9. doi: 10.1161/STROKEAHA.112.663708. Epub 2013 Jan 10.

Terryn W, Deschoenmakere G, De Keyser J, Meersseman W, Van Biesen W, Wuyts B, et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol. 2013;167(6):2555-60. doi: 10.1016/j.ijcard.2012.06.069.

Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, et al. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart. 201;97(23):1957-60. doi: 10.1136/heartjnl-2011-300364.

Zizzo C, Colomba P, Albeggiani G, Gallizzi R, Iemolo F, Nuzzo D, et al. Misdiagnosis of familial Mediterranean fever in patients with Anderson-Fabry disease. Clin Genet. 2013;83(6):576-81. doi: 10.1111/j.1399-0004.2012.01940.x.

Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, et al. Fabry disease 'The New Great Imposter': results of the French Observatoire in Internal Medicine Departments (FIMeD). Clin Genet. 2012;81(6):571-7. doi: 10.1111/j.1399-0004.2011.01718.x.

Huzmeli C, Candan F, Alaygut D, Bagci G, Akkaya L, Bagci B, Sozmen EY, Kurtulgan HK, Kayatas M. Prevalence of Fabry Disease in Familial Mediterranean Fever Patients from Central Anatolia of Turkey. Biochem Genet. 2016;54(4):448-456. doi: 10.1007/s10528-016-9731-3.

Niemann M, Rolfs A, Giese A, Mascher H, Breunig F, Ertl G, et al. Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease. JIMD Rep. 2013;7:99-102. doi: 10.1007/8904_2012_154. Epub 2012 Jul 1.

Effraimidis G, Rasmussen ÅK, Bundgaard H, Sørensen SS, Feldt-Rasmussen U. Is the alpha-galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic review. J Inherit Metab Dis. 2020;43(5):922-33. doi: 10.1002/jimd.12240.

Zompola C, Palaiodimou L, Kokotis P, Papadopoulou M, Theodorou A, Sabanis N, et al. The mutation D313Y may be associated with nervous system manifestations in Fabry disease. J Neurol Sci. 2020;412:116757. doi: 10.1016/j.jns.2020.116757.

Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003;80(3):307-14. doi: 10.1016/S1096-7192(03)00136-7.

Dubuc V, Moore DF, Gioia LC, Saposnik G, Selchen D, Lanthier S. Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22(8):1288-92. doi: 10.1016/j.jstrokecerebrovasdis.2012.10.005.

Turkmen K, Guclu A, Sahin G, Kocyigit I, Demirtas L, Erdur FM, et al. Kidney Blood Press Res. 2016;41(6):1016-24. doi: 10.1159/000452605. Epub 2016 Dec 23. PMID: 28006774.






Research Article

How to Cite

Kazan S, Dizen Kazan E, Tunca O, Araz M, Ulu S. Fabry disease prevalence in patients with familial Mediterranean fever: A cohort study. J Surg Med [Internet]. 2022 Jun. 1 [cited 2024 Jul. 23];6(6):601-4. Available from: https://jsurgmed.com/article/view/1004427